Predictive impact of systemic inflammation and tertiary lymphoid structures on pathological complete response in neoadjuvant-treated advanced esophageal squamous carcinoma patients
- 1 April 2026
- journal article
- Published by Elsevier in Pathology - Research and Practice
- Vol. 282, 156462
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Anhui Province (1808085QH271)
- Natural Science Foundation of Qingdao Municipality
This publication has 44 references indexed in Scilit:
- Unveiling the Role of Oligosaccharyltransferase STT3B in Colorectal Cancer Tissues: Clinical significance and Molecular Mechanisms Driving the Formation of Tertiary Lymphoid StructuresImmunobiology, 2025
- Exploring novel immunotherapy in advanced esophageal squamous cell carcinoma: Is targeting TIGIT an answer?Esophagus, 2025
- Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trialEuropean Journal of Cancer, 2024
- Survival benefit and spatial properties of tertiary lymphoid structures in esophageal squamous cell carcinoma with neoadjuvant therapiesCancer Letters, 2024
- STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgeryInternational Journal of Surgery, 2021
- Systemic inflammation markers and cancer incidence in the UK BiobankEuropean Journal of Epidemiology, 2021
- The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancerCancer Treatment Reviews, 2013
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating ImmunosurveillanceImmunity, 2013
- On the dual roles and polarized phenotypes of neutrophils in tumor development and progressionCritical Reviews in Oncology/Hematology, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011